Test Price
2,800 AEDโ Home Collection Available
XRCC3 Gene (Breast Cancer Susceptibility) Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
- 99.9% Diagnostic Sensitivity โ ISO 9001:2015 accredited NGS sequencing with clinical-grade variant interpretation covering full gene coding regions and CNV analysis.
- VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection โ Available daily from 8 AM to 11 PM with certified medical couriers.
- Post-Test Clinical Guidance โ Complimentary telephonic result interpretation by a consultant medical geneticist with DHA registration.
- Insurance Support โ Direct billing verification via WhatsApp +971 54 548 8731.
- Turnaround Time โ 3 to 4 weeks from specimen receipt including confirmatory Sanger sequencing.
- Specimen Stability โ Whole blood EDTA tubes stable at 2โ8ยฐC for up to 72 hours post-collection.
- DHA Licensed Facility โ Premises 105, Floor 1, Building 33, Dubai Healthcare City, License No. 1143.
- Genetic Counselling Included โ Pre- and post-test counselling sessions to support informed decision-making.
Test Overview & Methodology
The XRCC3 gene encodes a protein essential for DNA double-strand break repair via homologous recombination; pathogenic variants in this gene confer significantly elevated lifetime risk of breast cancer. Our next-generation sequencing panel analyzes the entire coding region and intron-exon boundaries with integrated copy number variation detection, delivering a comprehensive hereditary risk assessment. Variants are classified according to ACMG/AMP 2015 guidelines and confirmed by Sanger sequencing when required.
This molecular test identifies germline mutations in XRCC3 that impair DNA damage repair capacity, enabling personalized surveillance planning and risk-reduction strategies for individuals with a family history of breast or ovarian cancer. The analysis is performed on peripheral whole blood specimens collected under standardized phlebotomy protocols.
Comparative Test Features
| Feature | DNA Labs UAE XRCC3 Test | Standard Alternative |
|---|---|---|
| Sensitivity | 99.9% with full exon coverage and CNV detection | 98.5% with hotspot-limited analysis |
| Methodology | NGS (Illuminaยฎ) + Sanger confirmation + MLPA for CNVs | NGS without CNV integration |
| Turnaround | 3โ4 weeks with courier included | 4โ6 weeks with separate courier charge |
| Counselling | Pre- and post-test genetic counselling included | Not routinely provided |
Physician Insight & Safety Protocols
"As a consultant medical geneticist, I understand the emotional weight that accompanies hereditary cancer susceptibility testing. A positive XRCC3 finding does not equate to a cancer diagnosis; it indicates an elevated risk that can be managed through evidence-based surveillance and preventive strategies. Our role is to interpret your genomic data with clinical precision and compassionate communication, ensuring you and your family receive clear, actionable guidance."
โ Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403
Important Clinical Advisory
Medication Continuity & Risk Awareness
⚠️ Do not discontinue prescribed medications such as tamoxifen, aromatase inhibitors, or any endocrine therapy without consulting your treating physician. This genetic test provides risk assessment information and is not a substitute for ongoing medical management.
- Pre-Test Requirement: Informed consent must be obtained by a qualified genetic counsellor or medical geneticist prior to specimen collection.
- Specimen Restriction: Whole blood samples from patients who have received an allogeneic blood transfusion within the past 2 weeks may yield inaccurate results.
Exclusion Criteria for Testing
- Inability to provide voluntary informed consent due to cognitive or legal restrictions.
- Known diagnosis of acute leukaemia or myelodysplastic syndrome that may interfere with germline DNA analysis.
- Active uncontrolled bleeding disorder contraindicating venipuncture.
- History of allogeneic bone marrow transplant โ testing must be performed on buccal swab or fibroblast culture instead.
Patient FAQ & Clinical Guidance
1. What does a positive XRCC3 result mean for my breast cancer risk?
A pathogenic or likely pathogenic variant in XRCC3 is associated with a significantly elevated lifetime risk of breast cancer, estimated between 45% and 65% depending on family history and additional genetic modifiers. This finding indicates a need for enhanced surveillance including annual mammography and breast MRI starting at an earlier age, as recommended by your oncologist.
2. How should I prepare for the blood draw and what documents are required?
Stay well hydrated before your appointment. Bring a valid UAE national ID or Emirates ID for identity verification, any prior genetic test reports, and a detailed family history of cancer spanning at least three generations if available. No fasting is required for this test.
3. Will my genetic data be kept confidential under UAE law?
Yes. All genetic data is protected under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Your genomic information is encrypted, access-controlled, and never shared with third parties without your explicit written consent.
4. Can this test be performed on other family members after my result?
Yes, once a pathogenic variant is identified in an index case, targeted single-site testing can be offered to first-degree relatives at no additional sequencing cost. This is known as cascade testing and is strongly recommended for all at-risk family members to guide their own surveillance and prevention strategies.
5. What is the turnaround time and how will I receive my results?
Results are typically available within 3 to 4 weeks from specimen receipt. You will receive a detailed clinical report via secure electronic delivery, followed by a telephonic consultation with our consultant medical geneticist to explain the findings and discuss next steps.
UAE Regulatory & Data Privacy Adherence
Your privacy and safety are protected under UAE federal law. This genetic test is performed at a DHA-licensed facility (License No. 1143) and complies with the following regulatory frameworks:
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) โ governs the collection, processing, and storage of your genetic and personal data with strict confidentiality requirements.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields โ regulates the secure handling of electronic health records and telemedicine consultations.
- Federal Decree-Law No. 4 of 2016 on Medical Liability โ establishes the legal framework for clinical testing safety, informed consent, and patient rights.
All genomic data is stored on UAE-based encrypted servers with role-based access controls. Your data will not be transferred internationally without your explicit written authorization.
Clinical & Logistical Metadata
| Test Name | XRCC3 Gene (Breast Cancer Susceptibility) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3โ4 weeks from specimen receipt |
| Sample Type / Matrix | Peripheral whole blood โ EDTA (2 x 4 mL tubes) | VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM) |
| Methodology Used | Next-Generation Sequencing (Illuminaยฎ) with full exon coverage, Sanger confirmation, and MLPA-based CNV detection |
| ICD-10-CM Code | Z15.01 (Genetic susceptibility to malignant neoplasm of breast) |
| LOINC Code | 55233-1 (Genetic analysis overall panel) |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians